April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Targeted siRNA-Mediated Knockdown of p53 Family Activators ASPP1 and ASPP2 Delays Adult Retinal Ganglion Cell Death in vivo
Author Affiliations & Notes
  • A. M. Wilson
    Pathology/Cell Biology, University of Montreal, Montreal, Quebec, Canada
  • E. Feinstein
    Research, Quark Pharmaceuticals Inc, Ness Ziona, Israel
  • A. Di Polo
    Pathology/Cell Biology, University of Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  A.M. Wilson, None; E. Feinstein, Quark Pharmaceuticals Inc., E; A. Di Polo, None.
  • Footnotes
    Support  This study was supported by grants from Quark Pharmaceuticals Inc. and Canadian Institutes for Health Research (A.D.P.). A.W. is a recipient of a studentship in excellence from the FESP, UdM
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3720. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Wilson, E. Feinstein, A. Di Polo; Targeted siRNA-Mediated Knockdown of p53 Family Activators ASPP1 and ASPP2 Delays Adult Retinal Ganglion Cell Death in vivo. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3720.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The ASPP (Ankyrin-repeats, SH3-domain and Proline-rich-region-containing Protein) family members, ASPP1 and ASPP2, are essential regulators of p53 activity but their role in retinal ganglion cell (RGC) death is unknown. Here, we addressed their function in a rat model of acute optic nerve injury (axotomy) using novel siRNAs that selectively silence ASPP1 and ASPP2 gene expression.

Methods: : RGCs were retrogradely labeled by application of Fluorogold to the rat superior colliculus, and intraorbital optic nerve axotomy was performed one week later. siRNA against ASPP1, ASPP2 or GFP (control) were administered by intravitreal injection at the time of axotomy and one week after injury. The density of Fluorogold-labeled RGCs was quantified in 12 standard retinal areas at 1 and 2 weeks post-axotomy. ASPP protein expression was examined by retinal immunohistochemistry and western blot analysis.

Results: : Endogenous, retinal ASPP1 and ASPP2 proteins were found to be primarily expressed by RGCs, and were effectively knocked down as early as 24 hours after intravitreal injection of targeted siRNAs. ASPP1 and ASPP2 gene silencing led to robust protection of axotomized RGCs: ASPP2 and ASPP1 siRNA-injected eyes displayed 79% RGC survival (1,636 RGCs/mm2 ± 62, mean ± S.E.M., n=5) and 69% survival (1,423 RGCs/mm2 ± 19, n=4), respectively, compared to 54% that survived in GFP siRNA injected eyes (1,132±41 RGCs/mm2, n=5). Significant neuroprotection was also observed at two weeks post-axotomy: ~26% RGC survival was achieved with either ASPP1 or ASPP2, with respect to 6% in eyes treated with control siRNA.

Conclusions: : Our data demonstrate that targeted gene silencing of ASPP1 or ASPP2 effectively delays RGC death after acute optic nerve lesion, and suggest that ASPP proteins play an important role in the demise of these neurons following axonal injury.

Keywords: ganglion cells • neuroprotection • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×